108 related articles for article (PubMed ID: 14976343)
1. Correlation of tumors with DNA adducts from methyl eugenol and tamoxifen in rats.
Waddell WJ; Crooks NH; Carmichael PL
Toxicol Sci; 2004 May; 79(1):38-40. PubMed ID: 14976343
[TBL] [Abstract][Full Text] [Related]
2. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans.
Wild CP; Hasegawa R; Barraud L; Chutimataewin S; Chapot B; Ito N; Montesano R
Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):179-89. PubMed ID: 8833618
[TBL] [Abstract][Full Text] [Related]
3. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
4. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene.
Gamboa da Costa G; Pereira PC; Churchwell MI; Beland FA; Marques MM
Chem Res Toxicol; 2007 Feb; 20(2):300-10. PubMed ID: 17261033
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
6. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
Beland FA
Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
[TBL] [Abstract][Full Text] [Related]
7. Formation and repair of DNA adducts in vinyl chloride- and vinyl fluoride-induced carcinogenesis.
Swenberg JA; Bogdanffy MS; Ham A; Holt S; Kim A; Morinello EJ; Ranasinghe A; Scheller N; Upton PB
IARC Sci Publ; 1999; (150):29-43. PubMed ID: 10626206
[TBL] [Abstract][Full Text] [Related]
8. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.
Cupid BC; Lightfoot TJ; Russell D; Gant SJ; Turner PC; Dingley KH; Curtis KD; Leveson SH; Turteltaub KW; Garner RC
Food Chem Toxicol; 2004 Apr; 42(4):559-69. PubMed ID: 15019179
[TBL] [Abstract][Full Text] [Related]
9. Concordance of thresholds for carcinogenicity of N-nitrosodiethylamine.
Waddell WJ; Fukushima S; Williams GM
Arch Toxicol; 2006 Jun; 80(6):305-9. PubMed ID: 16308687
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis.
Tryndyak VP; Muskhelishvili L; Kovalchuk O; Rodriguez-Juarez R; Montgomery B; Churchwell MI; Ross SA; Beland FA; Pogribny IP
Carcinogenesis; 2006 Aug; 27(8):1713-20. PubMed ID: 16632870
[TBL] [Abstract][Full Text] [Related]
11. Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays.
Paini A; Scholz G; Marin-Kuan M; Schilter B; O'Brien J; van Bladeren PJ; Rietjens IM
Mutagenesis; 2011 Sep; 26(5):605-18. PubMed ID: 21642616
[TBL] [Abstract][Full Text] [Related]
12. Effects of intermittent exposure to aflatoxin B1 on DNA and RNA adduct formation in rat liver: dose-response and temporal patterns.
Sotomayor RE; Washington M; Nguyen L; Nyang'anyi R; Hinton DM; Chou M
Toxicol Sci; 2003 Jun; 73(2):329-38. PubMed ID: 12700393
[TBL] [Abstract][Full Text] [Related]
13. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
Mahadevan B; Arora V; Schild LJ; Keshava C; Cate ML; Iversen PL; Poirier MC; Weston A; Pereira C; Baird WM
Mol Carcinog; 2006 Feb; 45(2):118-25. PubMed ID: 16329150
[TBL] [Abstract][Full Text] [Related]
14. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of thresholds for carcinogenicity on linear and logarithmic dosage scales.
Waddell WJ
Hum Exp Toxicol; 2005 Jun; 24(6):325-32. PubMed ID: 16004200
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk assessment for crotonaldehyde and 2-hexenal: an approach.
Eder E; Schuler D; Budiawan
IARC Sci Publ; 1999; (150):219-32. PubMed ID: 10626223
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
[TBL] [Abstract][Full Text] [Related]
18. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells.
Lee JH; Lu HF; Wang DY; Chen DR; Su CC; Chen YS; Yang JH; Chung JG
Res Commun Mol Pathol Pharmacol; 2004; 115-116():217-33. PubMed ID: 17564319
[TBL] [Abstract][Full Text] [Related]
19. Intestinal tumorigenesis in multiple intestinal neoplasia mice induced by the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine: perinatal susceptibility, regional variation, and correlation with DNA adducts.
Steffensen IL; Schut HA; Paulsen JE; Andreassen A; Alexander J
Cancer Res; 2001 Dec; 61(24):8689-96. PubMed ID: 11751386
[TBL] [Abstract][Full Text] [Related]
20. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM
Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
